GlassScriptPhysician profile
Nisha Navin Patel
NPI 1679269815
$3,190.19
in general payments reported to CMS, 2019-2025
30 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $518 · 2024: $1,439 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $27.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.84 |
| Education | $27.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.42 | 2023-2025 | |
| Qol Medical, LLC | $267.59 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $248.59 | 2024-2025 | Rybrevant, Carvykti, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.73 | 2024-2025 | Xifaxan |
| Pfizer INC. | $114.20 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $102.25 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $81.60 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Neuraxis, INC. | $76.13 | 2025 | |
| Celltrion USA INC. | $74.99 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $74.36 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $73.57 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $64.23 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $63.49 | 2023-2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $63.40 | 2024 | |
| Endo USA, INC. | $61.17 | 2025 | Aveed, Xiaflex |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.75 | 2025 | |
| Lucid Diagnostics INC. | $50.49 | 2024 | |
| Madrigal Pharmaceuticals | $48.20 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $44.64 | 2025 | Axonics |
| Urogen Pharma, INC. | $38.25 | 2025 | |
| Teleflex LLC | $26.29 | 2025 | Barrigel |
| Astrazeneca Pharmaceuticals LP | $24.91 | 2023 | Andexxa |
| Merck Sharp & Dohme LLC | $24.06 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $23.42 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $21.26 | 2024 | Sutab, Suflave |
| Sumitomo Pharma America, INC. | $20.53 | 2025 | Orgovyx |
| Vivus LLC | $20.52 | 2024 | Pancreaze |
| Genzyme Corporation | $16.61 | 2024 | |
| Bioprotect Medical, INC. | $16.60 | 2025 | Bioprotect Balloon Implant System |
| 180 Medical, INC. | $15.94 | 2025 | Gentlecath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.